IVI Introduces Transparent Approach for Value Assessment
The Innovation and Value Initiative (IVI) released its first assessment of treatments for rheumatoid arthritis using its new approach toward value assessment. NPC is still evaluating IVI’s new framework and methodology, but we are cautiously optimistic about several attributes of IVI’s approach.
Where Are They Now: Checking In With Former NPC Fellow Chuck Shih
Chuck Shih, PhD, MHS, currently Associate Director, Healthcare Reform and Public Policy at Biogen, was the 2013-2015 NPC Health Policy Fellow as part of a partnership with the George Washington University Milken Institute School of Public Health. Dr. Shih chatted with us about how his time at NPC impacted his work and career.
NAMI Weighs in on Value Assessment and ICER Engagement
Andrew Sperling, Director of Legislative Advocacy for the National Alliance on Mental Illness (NAMI), caught up with NPC President Dan Leonard to chat about concerns raised by mental health advocates on the approach the Institute for Clinical and Economic Review has used to evaluate the value of tardive dyskinesia treatments.